Combining treatment for chronic hepatitis C with opioid agonist therapy is an effective microelimination strategy for people who inject drugs with high risk of non-adherence to direct-acting antiviral therapy

BACKGROUND & AIMS: Despite effective direct-acting antivirals (DAAs), hepatitis C virus (HCV) prevalence is high among people who inject drugs (PWIDs) and non-adherence to therapy remains a major obstacle towards HCV elimination in this subpopulation. To overcome this issue, we have combined ong...

Descripción completa

Detalles Bibliográficos
Autores principales: Schwarz, M., Schwarz, C., Schütz, A., Schwanke, C., Krabb, E., Schubert, R., Liebich, S.-T., Bauer, D., Burghart, L., Brinkmann, L., Gutic, E., Reiberger, T., Haltmayer, H., Gschwantler, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10036924/
https://www.ncbi.nlm.nih.gov/pubmed/36970063
http://dx.doi.org/10.1016/j.jve.2023.100319

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10036924/
https://www.ncbi.nlm.nih.gov/pubmed/36970063
http://dx.doi.org/10.1016/j.jve.2023.100319

Ejemplares similares